SRC and malignant glioma: Indeed, after a thorough investigation that included in vitro and in vivo models, such as intracranial implantation of murine glioma cells and GSCs into immunocompetent mice and of human GSCs into immunosuppressed mice, we can conclude that TAT-Cx43266–283 prolongs the survival of glioma-bearing mice because it reduces the growth, invasion, and progression of malignant gliomas with remarkably fewer toxic effects for normal brain cells than other c-Src inhibitors currently being tested in glioma clinical trials.